<DOC>
	<DOCNO>NCT01626560</DOCNO>
	<brief_summary>Primary : To determine influence daptomycin inflammatory cytokine ( IL-1 , TNF IL-6 ) treatment complicate cellulitis/erysipela compare alternative treatment ( vancomycin oxacillin ) . Secondary : To evaluate clinical outcome group accord level cytokine evaluate .</brief_summary>
	<brief_title>The Effects Daptomycin Cytokines Production Comparison With Vancomycin</brief_title>
	<detailed_description />
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Daptomycin</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<criteria>1 . Eligible patient age 18 65 require hospitalization parenteral antimicrobial therapy 2 . Clinical documentation cellulitis / erysipela 3 . Documentation minimal surface area 75 cm2 base length / width redness , swell / induration 4 . Documented fever , define oral tympanic temperature great equal 38 Â° C 1 . Infections minor addition erysipelas / cellulitis 2 . Any recent use antibacterial drug therapy ( systemic topical antibacterial drug within 14 day enrollment ) 3 . Patients clinical condition alter interpretation primary outcome patient neutropenia compromise immune function , HIV infection , autoimmune disorder , use corticosteroid . 4 . Patients know suspected osteomyelitis . 5 . Patients suspect confirmed septic arthritis . 6 . Patients complicate skin infection , diabetic foot infection . 7 . Chronic use antipyretic drug ( eg , daily use naproxen ) . 8 . Less 18 year age . 9. pregnancy 10 . Patients mixed infection Gramnegative delete since therapy gramnegative influence level cytokine . 11 . Patients renal clearance &lt; 30 mL / min . 12 . Patients susceptible daptomycin vancomycin . 13 . Allergy study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>